Pharmacotherapy for Seizures in Tuberous Sclerosis Complex.

Abstract

Epilepsy is one of the main symptoms affecting the lives of individuals with tuberous sclerosis complex (TSC), causing a high rate of morbidity. Individuals with TSC can present with various types of seizures, epilepsies, and epilepsy syndromes that can coexist or appear in relation to age. Focal epilepsy is the most frequent epilepsy type with two developmental and epileptic encephalopathies: infantile spasms syndrome and Lennox-Gastaut syndrome. Active screening and early management of epilepsy is recommended in individuals with TSC to limit its consequences and its impact on quality of life, cognitive outcome and the economic burden of the disease. The progress in the knowledge of the mechanisms underlying epilepsy in TSC has paved the way for new concepts in the management of epilepsy related to TSC. In addition, we are moving from traditional "reactive" and therapeutic choices with current antiseizure medications used after the onset of seizures, to a proactive approach, aimed at predicting and preventing epileptogenesis and the onset of epilepsy with vigabatrin, and to personalized treatments with mechanistic therapies, namely mechanistic/mammalian target of rapamycin inhibitors. Indeed, epilepsy linked to TSC is one of the only epilepsies for which a predictive and preventive approach can delay seizure onset and improve seizure response. However, the efficacy of such interventions on long-term cognitive and psychiatric outcomes is still under investigation.

• Authors: Rima Nabbout, Mathieu Kuchenbuch, Catherine Chiron, Paolo Curatolo
• Journal: CNS drugs (CNS Drugs) Vol. 35 Issue 9 Pg. 965-983 (09 2021) ISSN: 1179-1934 [Electronic] New Zealand
• PMID: 34417984 (Publication Type: Journal Article, Review)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Chemical References

• Anticonvulsants
• MTOR Inhibitors
• Cannabidiol
• Vigabatrin

Topics

• Anticonvulsants (therapeutic use)
• Cannabidiol (therapeutic use)
• Humans
• MTOR Inhibitors (therapeutic use)
• Seizures (drug therapy, epidemiology, physiopathology)
• Tuberous Sclerosis (drug therapy, epidemiology, physiopathology)
• Vigabatrin (therapeutic use)